Latest

Learn how antibiotic-resistant UTI testing identifies ESBL, CRE, resistance genes, and antibiotic susceptibility, and how culture results guide treatment and follow-up.

Antibiotic-Resistant UTI Test: ESBL, CRE, Resistance Markers, and Culture Meaning

Learn what asymptomatic bacteriuria means, how a positive urine culture without UTI symptoms is interpreted, and when screening, treatment, or follow-up matters.

Asymptomatic Bacteriuria Test: Positive Culture Without Symptoms and When It Matters

Learn how bacteria in urine are interpreted using urinalysis, culture, colony count, symptoms, and sample quality, including when contamination or follow-up testing matters.

Bacteria in Urine Test: UTI, Contamination, Colony Count, and Culture Follow-Up

Learn how a catheter urine culture helps diagnose catheter-associated UTI, how samples are collected, and what colony counts, pyuria, resistance, and positive results mean.

Catheter Urine Culture Test: Catheter-Associated UTI and Culture Meaning

Learn how a chlamydia and gonorrhea urine NAAT works, how to collect first-catch urine, what positive or negative results mean, and when follow-up testing is needed.

Chlamydia and Gonorrhea Urine NAAT Test: STI Screening, Positive Result, and Meaning

Learn how to collect a clean-catch urine culture, reduce contamination, handle the sample correctly, and understand mixed flora, colony counts, repeat testing, and accurate results.

Clean-Catch Urine Culture Test: Sample Collection, Contamination, and Accurate Results

Diagnostics

Home Diagnostics Page 88

Learn what PALB2 genetic testing shows, how pathogenic variants affect breast, pancreatic, and ovarian cancer risk, and how positive, negative, and VUS results guide care.

PALB2 Genetic Test: Breast Cancer Risk, Mutations, and Results

Learn how PDGFRA mutation testing guides GIST diagnosis and therapy, including D842V, exon 18 results, imatinib resistance, avapritinib, and follow-up.

PDGFRA Mutation Test: GIST, Targeted Therapy, and Results

Learn how PD-L1 testing guides cancer immunotherapy, including TPS, CPS, assay clones, positive and negative scores, cancer-specific cutoffs, and test limitations.

PD-L1 Test: Cancer Immunotherapy, Expression Score, and Results

Learn how PIK3CA mutation testing guides targeted therapy in HR-positive, HER2-negative advanced breast cancer, including tissue, plasma, alpelisib, and inavolisib results.

PIK3CA Mutation Test: Breast Cancer, Targeted Therapy, and Results

Learn how PML-RARA testing confirms acute promyelocytic leukemia, compares FISH with RT-PCR, guides ATRA and arsenic treatment, and monitors molecular remission.

PML-RARA Test: Acute Promyelocytic Leukemia, Fusion Gene, and Results

Learn what an PMS2 genetic test shows, how results relate to Lynch syndrome and colon cancer risk, and what positive, negative, and uncertain findings mean for care and family.

PMS2 Genetic Test: Lynch Syndrome, Colon Cancer Risk, and Results

Learn how PTEN genetic testing can confirm Cowden syndrome, clarify cancer risks, explain positive, negative, and VUS results, and guide screening for patients and families.

PTEN Genetic Test: Cowden Syndrome, Cancer Risk, and Results

Understand how RB1 genetic testing identifies heritable retinoblastoma, clarifies blood and tumor results, guides eye surveillance, and defines cancer and family risks.

RB1 Genetic Test: Retinoblastoma, Cancer Risk, and Results

Learn how RET fusion testing detects targetable drivers in lung and thyroid cancer, how RNA and DNA methods differ, and what positive, negative, and resistance results mean.

RET Fusion Test: Lung and Thyroid Cancer, Targeted Therapy, and Results

Learn how germline RET testing confirms MEN2, guides medullary thyroid cancer prevention, explains variant results, and directs pheochromocytoma screening and family testing.

RET Genetic Test: MEN2, Medullary Thyroid Cancer, and Results

Learn how a ROS1 fusion test detects an actionable lung cancer driver, how tissue and blood methods differ, and what positive, negative, and resistance results mean.

ROS1 Fusion Test: Lung Cancer, Targeted Therapy, and Results

Understand what an SDHB genetic test shows, how results affect paraganglioma and pheochromocytoma surveillance, metastatic risk, and testing for relatives.

SDHB Genetic Test: Paraganglioma, Pheochromocytoma, and Cancer Risk

Learn how an SDHC genetic test identifies hereditary paraganglioma risk, what positive, negative, and VUS results mean, and how carrier surveillance works.

SDHC Genetic Test: Paraganglioma, Pheochromocytoma, and Results

Learn how an SDHD genetic test identifies hereditary paraganglioma risk, why paternal inheritance matters, and how positive, negative, and uncertain results guide surveillance.

SDHD Genetic Test: Paraganglioma, Pheochromocytoma, and Results

Learn how a solid tumor NGS panel detects cancer mutations, fusions, copy-number changes, and biomarkers, and how results may guide treatment, trials, and repeat testing.

Solid Tumor NGS Panel Test: Cancer Mutations, Fusions, and Treatment Results

Learn what an STK11 genetic test shows, how Peutz-Jeghers syndrome affects polyps and cancer risk, and what positive, negative, and VUS results mean for surveillance.

STK11 Genetic Test: Peutz-Jeghers Syndrome, Cancer Risk, and Results

1...878889...137 Page 88 of 137